Scholar Rock experienced a dramatic surge in its stock price on October 7, 2024, after announcing positive results from its Phase 3 SAPPHIRE clinical trial for apitegromab, a promising treatment for spinal muscular atrophy (SMA).
This article This drug just changed the game for spinal muscular atrophy—315% stock surge?! The breakthrough EVERYONE is talking about! 🚀 appeared first on Guerilla Stock Trading.